Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer.
- Resource Type
- Article
- Authors
- Kelly, Richard; Jensen, Andrew; Karunaratna, Nathasha; Wong, Shirley; Shapiro, Julia; Weickhardt, Andrew; Parente, Phillip; Azad, Arun A.; Uccellini, Anthony; Torres, Javier; Parnis, Francis; Goh, Jeffrey; Kwan, Edmond M.; Brown, Stephen; Steer, Christopher; Warren, Mark; Gibbs, Peter; Tran, Ben; Anton, Angelyn
- Source
- BJU International. Feb2023, Vol. 131 Issue 2, p179-182. 4p.
- Subject
- *CASTRATION-resistant prostate cancer
*POSITRON emission tomography computed tomography
*PROSTATE-specific membrane antigen
*POSITRON emission tomography
- Language
- ISSN
- 1464-4096
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer Abbreviations (m)CRPC (metastatic) castration-resistant prostate cancer ePAD electronic Prostate Cancer Australian Database FDG fluorodeoxyglucose HSPC hormone-sensitive prostate cancer LN lymph nodes PET positron emission tomography PSMA prostate-specific membrane antigen WBBS whole-body bone scan Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-CT imaging has demonstrated greater sensitivity compared to conventional imaging modalities with CT and whole-body bone scan (WBBS) in the detection of metastatic prostate cancer [[1]]. A further 15 patients (17%) had dedicated CT alone in addition to PSMA PET-CT, while eight (9%) had additional WBBS alone in addition to PSMA PET-CT (Fig. [Extracted from the article]